Susan C Bates

List of Publications by Year
in descending order

111 papers	6,525 citations	125106 35 h-index	75989 78 g-index
166 all docs	166 docs citations	166 times ranked	9733 citing authors

#	Article	IF	Citations
1	Equipoise, drug development, and biliary cancer. Cancer, 2022, 128, 944-949.	2.0	3
2	Costâ€effectiveness of neoadjuvant <scp>FOLFIRINOX</scp> versus gemcitabine plus nabâ€paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 2022, 5, e1565.	0.6	4
3	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 2022, 11, 2066767.	2.1	9
4	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. Cancers, 2022, 14, 2643.	1.7	2
5	Supreme Court and the Practice of Oncology. Oncologist, 2022, 27, 427-427.	1.9	1
6	Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. Oncotarget, 2021, 12, 15-21.	0.8	5
7	Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Seminars in Oncology, 2021, 48, 34-46.	0.8	7
8	Gemcitabine plus nabâ€paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Seminars in Oncology, 2021, 48, 69-75.	0.8	4
9	Emergency Department Visits for Emesis Following Chemotherapy: Guideline Nonadherence, OP â€35, and a Path Back to the Future. Oncologist, 2021, 26, 274-276.	1.9	3
10	R-Loopâ€“Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin. Molecular Cancer Research, 2021, 19, 1361-1374.	1.5	12
11	Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance. Nature Communications, 2021, 12, 2804.	5.8	77
12	Positive attitudes toward clinical trials among military veterans leaves unanswered questions about poor trial accrual. Seminars in Oncology, 2021, 48, 130-140.	0.8	2
13	Antibiotics and Imiquimod for Cutaneous Tâ€Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure. Oncologist, 2021, 26, 727.	1.9	1
14	Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. Molecular Cancer Therapeutics, 2021, 20, 1422-1430.	1.9	6
15	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	1.8	13
16	Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma. , 2021, 62, 16.		4
17	Adenocarcinoma of the Pancreas: Past, Present, Future. Seminars in Oncology, 2021, 48, 1.	0.8	0
18	Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. Oncologist, 2020, 25, 132-139.	1.9	15

#	Article	IF	Citations
19	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. Cancer Biology and Therapy, 2020, 21, 223-230.	1.5	10
20	Epigenetic Therapies for Cancer. New England Journal of Medicine, 2020, 383, 650-663.	13.9	289
21	Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2020, 38, 3185-3194.	0.8	233
22	Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. BMC Medical Genomics, 2020, 13, 165.	0.7	15
23	BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects . Cancer Management and Research, 2020, Volume 12, 2731-2742.	0.9	69
24	Emerging Therapeutic Implications of STK11 Mutation: Case Series. Oncologist, 2020, 25, 733-737.	1.9	31
25	Accrual, Publication Bias, and the Coronavirus in 2020. Oncologist, 2020, 25, e1001-e1002.	1.9	2
26	ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. Oncotarget, 2020, 11, 3432-3442.	0.8	5
27	Publish or Perish v2. Oncologist, 2019, 24, 723-724.	1.9	1
28	Exploring the Impact of Dust on North Atlantic Hurricanes in a Highâ€Resolution Climate Model. Geophysical Research Letters, 2019, 46, 1105-1112.	1.5	26
29	Targeting Translation of mRNA as a Therapeutic Strategy in Cancer. Current Hematologic Malignancy Reports, 2019, 14, 219-227.	1.2	31
30	PDâ€1 Pandemonium at the American Association for Cancer Research Annual Meeting. Oncologist, 2019, 24, 571-573.	1.9	1
31	A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Seminars in Oncology, 2019, 46, 351-361.	0.8	15
32	Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models. Experimental Cell Research, 2019, 375, 106-112.	1.2	15
33	Neoadjuvant Treatment for Pancreatic Cancer. Seminars in Oncology, 2019, 46, 19-27.	0.8	76
34	VA Cancer Research: A Legacy and A Future. Seminars in Oncology, 2019, 46, 305-307.	0.8	1
35	Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: InÂvitro and inÂvivo. Cancer Letters, 2018, 424, 19-29.	3.2	42
36	Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018, 18, 452-464.	12.8	1,181

#	Article	IF	Citations
37	Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs, 2018, 29, 457-465.	0.7	39
38	Internal climate variability and projected future regional steric and dynamic sea level rise. Nature Communications, 2018, 9, 1068.	5.8	40
39	Projected changes in tropical cyclone activity under future warming scenarios using a high-resolution climate model. Climatic Change, 2018, 146, 547-560.	1.7	142
40	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leukemia and Lymphoma, 2018, 59, 880-887.	0.6	28
41	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2018, 36, 1594-1602.	0.8	122
42	Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research. Oncologist, 2018, 23, 1391-1393.	1.9	3
43	Entinostat finds a path: A new study elucidates effects of the histone deacetylase inhibitor on the immune system. Cancer, 2018, 124, 4597-4600.	2.0	5
44	Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma. American Journal of Clinical Dermatology, 2018, 19, 805-819.	3.3	38
45	A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer Chemotherapy and Pharmacology, 2018, 82, 565-570.	1.1	6
46	Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia and Lymphoma, 2017, 58, 2335-2341.	0.6	13
47	Too Many Journals. Oncologist, 2017, 22, 126-128.	1.9	5
48	Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chemico-Biological Interactions, 2017, 273, 171-179.	1.7	23
49	Pancreatic Cancer: â€œA Riddle Wrapped in a Mystery inside an Enigmaâ€• Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38
50	Pancreatic Cancer: Challenge and Inspiration. Clinical Cancer Research, 2017, 23, 1628-1628.	3.2	11
51	Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncology, The, 2017, 18, 143-154.	5.1	68
52	Clinical Trials in Pancreatic Cancer: A Long Slog. Oncologist, 2017, 22, 1424-1426.	1.9	7
53	Refining Immunotherapy Approvals. Clinical Cancer Research, 2017, 23, 4948-4949.	3.2	9
54	Base Pairs to Populations. Clinical Cancer Research, 2017, 23, 2610-2610.	3.2	0

#	Article	IF	Citations
55	Current challenges in the management of breast cancer brain metastases. Seminars in Oncology, 2017, 44, 85-100.	0.8	44
56	Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48â€hour continuous infusion in patients with cancer. Journal of Clinical Pharmacology, 2016, 56, 461-473.	1.0	32
57	Romidepsin Therapy Over 5 Years in a Clinical Settingâ€"Real-world Experience. JAMA Oncology, 2016, 2, 794.	3.4	2
58	Disruptive Immunology. Clinical Cancer Research, 2016, 22, 1844-1844.	3.2	1
59	Endocrine Cancers: Defying the Paradigms. Clinical Cancer Research, 2016, 22, 4980-4980.	3.2	4
60	Multiple Myeloma: Multiplying Therapies. Clinical Cancer Research, 2016, 22, 5418-5418.	3.2	6
61	Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. Clinical Cancer Research, 2016, 22, 4989-5000.	3.2	15
62	UGT1A1 genotypeâ€dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of Clinical Pharmacology, 2016, 56, 450-460.	1.0	19
63	Phase I Testing: 60 Years in the Making. Clinical Cancer Research, 2016, 22, 2612-2612.	3.2	0
64	Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting. Oncologist, 2016, 21, 261-268.	1.9	30
65	New drug for pancreatic cancer highlights the dual effect of regulatory approvals. Nature Reviews Clinical Oncology, 2016, 13, 205-206.	12.5	7
66	Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget, 2016, 7, 69804-69815.	0.8	14
67	Romidepsin in peripheral and cutaneous Tâ€cell lymphoma: mechanistic implications from clinical and correlative data. British Journal of Haematology, 2015, 170, 96-109.	1.2	51
68	Advancing Clinical Trials to Streamline Drug Development. Clinical Cancer Research, 2015, 21, 4527-4535.	3.2	29
69	Targeting KRAS and the vitamin D receptor via microtubules. Nature Reviews Clinical Oncology, 2015, 12, 442-444.	12.5	4
70	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research, 2015, 21, 2096-2106.	3.2	48
71	How Do Cancer Cells Die?. Clinical Cancer Research, 2015, 21, 5014-5014.	3.2	0
72	Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. PLoS ONE, 2014, 9, e96316.	1.1	26

#	Article	IF	Citations
73	Developing Precision Medicine in a Global World. Clinical Cancer Research, 2014, 20, 1419-1427.	3.2	36
74	Therapies with Diverse Mechanisms of Action Kill Cells by a Similar Exponential Process in Advanced Cancers. Cancer Research, 2014, 74, 4653-4662.	0.4	9
75	Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice. Clinical Cancer Research, 2014, 20, 5240-5254.	3.2	40
76	Histone deacetylase inhibitorâ€mediated cell death is distinct from its global effect on chromatin. Molecular Oncology, 2014, 8, 1379-1392.	2.1	39
77	Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2. Oncotarget, 2014, 5, 4529-4542.	0.8	41
78	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers. Clinical Cancer Research, 2013, 19, 4499-4507.	3.2	55
79	Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle, 2013, 12, 2829-2838.	1.3	24
80	MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood, 2013, 121, 4115-4125.	0.6	69
81	Drug Development: Portals of Discovery. Clinical Cancer Research, 2012, 18, 23-32.	3.2	37
82	Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer. Cell Cycle, 2011, 10, 3119-3128.	1.3	45
83	Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, 2011, 117, 5827-5834.	0.6	428
84	Assessment of Tumor Growth (g) and Regression (d) Rate Constants in Patients with Multiple Myeloma (MM) Shows That the Superiority of Bortezomib with Liposomal Doxorubicin (PLD+B) Over Bortezomib Alone (B) Is a Result of Reduced Growth of Refractory Tumor Cells and Not of Higher Regression Rates, and Provides An Earlier Efficacy Endpoint That Allows for Comparison Across Trials. Blood, 2011, 118, 5113-5113.	0.6	0
85	Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral Tâ€cell lymphoma. British Journal of Haematology, 2010, 148, 256-267.	1.2	74
86	Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy, 2010, 10, 997-1008.	1.1	215
87	Epigenetic Modulation and Therapy of Lymphoid Malignancies. Blood, 2010, 116, SCI-30-SCI-30.	0.6	0
88	Commentary: Troublesome Words, Linguistic Precision, and Medical Oncology. Oncologist, 2009, 14, 445-447.	1.9	3
89	Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 5410-5417.	0.8	687
90	Epigenetic Modifiers: Basic Understanding and Clinical Development. Clinical Cancer Research, 2009, 15, 3918-3926.	3.2	135

#	Article	IF	Citations
91	Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data. Oncologist, 2008, 13, 1046-1054.	1.9	81
92	Histone Deacetylase Inhibitors in Combinations: Will the Preclinical Promises Be Kept?. Cancer Journal (Sudbury, Mass), 2007, 13, 80-83.	1.0	7
93	Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176). Clinical Cancer Research, 2006, 12, 1547-1555.	3.2	97
94	T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood, 2004, 103, 4636-4643.	0.6	188
95	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. , 2002, 94, 2333.		1
96	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood, 2001, 98, 2865-2868.	0.6	458
97	An ATP-binding cassette gene (ABCG3) closely related to the multidrug transporter ABCG2 (MXR/ABCP) has an unusual ATP-binding domain. Mammalian Genome, 2001, 12, 86-88.	1.0	32
98	New ABC transporters in multi-drug resistance. Expert Opinion on Therapeutic Targets, 2000, 4, 561-580.	1.0	6
99	FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anti-Cancer Drugs, 2000, 11, 445-454.	0.7	35
100	Amplification of 4q21-q22 and theMXR gene in independently derived mitoxantrone-resistant cell lines. , 2000, 27, 110-116.		73
101	Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay. Blood, 1997, 89, 3795-3800.	0.6	32
102	Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration. Cancer Chemotherapy and Pharmacology, 1997, 40, 245-250.	1.1	28
103	Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. Journal of Cellular Biochemistry, 1997, 65, 513-526.	1.2	87
104	Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay. Blood, 1997, 89, 3795-3800.	0.6	1
105	Clinical Reversal of Multidrug Resistance. Stem Cells, 1996, 14, 56-63.	1.4	31
106	Clinical Reversal of Multidrug Resistance. Oncologist, 1996, 1, 269-275.	1.9	5
107	Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. Journal of Cellular Physiology, 1993, 157, 110-118.	2.0	37
108	Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. International Journal of Cancer, 1991, 49, 688-695.	2.3	63

#	Article	IF	Citations
109	The Use and Potential of Serum Tumour Markers, New and Old. Drugs, 1989, 38, 9-18.	4.9	5
110	Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. Journal of Cellular Biochemistry, 1987, 35, 1-16.	1.2	111
111	Reversal of Multidrug Resistance: Lessons from Clinical Oncology. Novartis Foundation Symposium, 0, , 83-102.	1.2	59